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Abstract
Background: Inflammatory myofibroblastic tumor (IMT) is a rare low-grade malignant neoplasm with a predilection
for children and young adults, and typically arises in the lung, abdominopelvic region, and retroperitoneum. IMTs in
the maxillofacial region are extreme rare. Approximately 50% of IMT harbor rearrangements of the anaplastic
lymphoma kinase (ALK) gene at 2p23 with various fusion partners.
Case presentation: We herein report a case of intraosseous IMT of the mandible with a novel ATIC-ALK fusion.
Tooth 43 did not erupt after the loss of tooth 83 in an 11-year-old girl with no previous history of trauma.
Panoramic tomography showed a unilocular radiolucent lesion in the right anterior mandible resorbing the root of
tooth 42 and the medial side of the root of tooth 44. Computed tomography revealed a well- circumscribed 3-cm
osteolytic lesion of the right anterior mandible eroding the buccal cortical plate. The entire lesion was curetted out.
A histopathological examination revealed the proliferation of plump spindle cells with a storiform architecture and
lymphocytes scattered around spindle cells. The spindle cells showed diffuse cytoplasmic staining for ALK by
immunohistochemistry. A fluorescence in situ hybridization analysis revealed the translocation of a part of the ALK
gene locus at chromosome 2p23. A rapid amplification of cDNA ends analysis confirmed the rearrangement of ALK
and identified ATIC as a partner of this ALK fusion mutant.
Conclusion: To the best of our knowledge, this is the first case of intraosseous IMT of the mandible with a novel
ATIC-ALK fusion. We also herein reviewed similar tumors reported in the literature.
Keywords: Inflammatory myofibroblastic tumor, Mandible, Anaplastic lymphoma kinase gene, ATIC-ALK fusion,
Fluorescence in situ hybridization, 5′ rapid amplification of cDNA ends, RT-PCR
Background
Inflammatory myofibroblastic tumors (IMTs) are more
frequent in children and young adults, and typically arise
in the lung, abdominopelvic region, and retroperitoneum
[1, 2]. Unusual sites of involvement include the head and
neck, genitourinary tract, heart, extremities, and central
nervous system [2]. While these tumors are rare in the
head and neck, they are even more uncommon in the
mandible [3].
IMTs are mesenchymal neoplasms of intermediate ma-
lignant potential and histologically characterized by the
proliferation of fibroblasts and myofibroblasts admixed
with lymphocytes, plasma cells, eosinophils, and histio-
cytes [1]. The histological features of IMTs are often diag-
nostic, particularly through anaplastic lymphoma kinase
(ALK) staining. The ALK gene has been implicated in the
pathogenesis of IMTs, which supports the neoplastic ori-
gin of these tumors. Approximately 50% of IMTs harbor
rearrangements in the ALK gene at 2p23 [4]. However, to
the best of our knowledge, an ALK fusion mutation has
not yet been demonstrated in IMTs in the jawbone.
We herein report a case of an intraosseous IMT in the
mandible including a novel ATIC-ALK fusion mutation.
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An 11-year-old girl presented with the delayed eruption
of tooth 43 (two digit tooth notation system of the FDI)
and mental nerve palsy. She had no history of trauma.
An intraoral examination revealed that tooth 43 had not
erupted after the loss of tooth 83 and the gingiva and al-
veolar mucosa of the right mandible were normal. Pano-
ramic tomography showed a unilocular radiolucent lesion
in the right anterior mandible resorbing the root of
tooth 42 and the medial side of the root of tooth 44
(Fig. 1a). Tooth 43 was not impacted in the mandibu-
lar bone. Computed tomography showed a well-
circumscribed non-expansile 3-cm osteolytic lesion in
the right anterior mandible that eroded the buccal
cortical plate and resorbed the root of tooth 42 and
the medial side of the root of tooth 44 (Fig. 1b). Root
resorption and cortical plate erosion suggested a locally
aggressive tumor. The tumor lesion was entirely cu-
retted out. No recurrence was detected in 18 months
of follow-up.
Histopathological features and differential diagnosis
A histopathological investigation revealed plump spindle
cell proliferation with a storiform architecture and lym-
phocytes scattered around the spindle cells (Fig. 2a, b).
The background stroma included a focal myxoid matrix.
These spindle cells had ovoid nuclei with a pale eosino-
philic cytoplasm, suggesting a myofibroblastic, myoepithe-
lial, or fibroblastic lineage. Small islands of an odontogenic
epithelium were detected. No mitosis or necrosis was ob-
served. The histomorphological findings suggested that
spindle cells were of a myofibroblastic, myoepithelial,
or fibroblastic lineage. Small islands of an odonto-
genic epithelium suggested that this tumor was an
Fig. 1 a Panoramic tomography showed the resorption of the root of tooth 42 and medial side of the root of tooth 44 (arrow heads). b
Computed tomography revealed a well- circumscribed 3-cm osteolytic lesion in the right mandible that eroded the buccal cortical plate and
resorbed the roots of tooth 42 and tooth 44 (arrows)
Fig. 2 Hematoxylin and eosin staining (a, b) and immunohistochemical staining (c, d). a The proliferation of plump spindle cells with a storiform
architecture with scattered lymphocytes. Epithelioid components with an appearance suggestive of odontogenic epithelioid cells were detected. b
Spindle cells contained ovoid nuclei with a pale eosinophilic cytoplasm. c Spindle cells were positive for SMA. d Spindle cells were positive for ALK
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odontogenic tumor. High-grade malignant tumors were
excluded because neither mitosis nor necrosis was ob-
served. Differential diagnoses included myofibroma, myoe-
pithelioma, an odontogenic tumor, solitary fibrous tumor,
giant cell granuloma, and IMT.
Immunohistochemical findings
Immunohistochemical staining revealed that spindle cells
were positive for α-smooth muscle actin (SMA) (Fig. 2c),
ALK (Fig. 2d), CD10, and glial fibrillary acidic protein
(GFAP), and negative for cytokeratin AE1/AE3, S100 pro-
teins, and p63. The Ki67 labeling index was 3%.
Molecular pathological findings
FISH
A fluorescence in situ hybridization (FISH) (ALK) analysis
was performed on a formalin-fixed paraffin-embedded
(FFPE) tissue block. Rearrangements in the ALK gene at
chromosome band 2p23 were detected by FISH utilizing a
Vysis ALK break apart probe (Abott Molecular). The
FISH analysis revealed the translocation of a part of the
ALK gene locus (Fig. 3a).
RACE
Total RNA was extracted from frozen tissue using an
RNeasy mini kit (Qiagen) according to the manufac-
turer’s instructions. In order to obtain cDNA fragments
corresponding to a novel ALK fusion gene, a rapid amp-
lification of cDNA ends (RACE) analysis was performed
using the 5′-full RACE core set (TaKaRa Bio) according
to the manufacturer’s instructions. First-strand cDNA
synthesis was performed with a 5′ end-phosphorylated
RT primer (5′-ATCTGGGCCTTGTATTTATCACTC).
The primer set used for the first round of PCR was the
A1 primer (5′-ACTTCCTGGTTGCTTTTGCTGGGG
TAT) [5] and S1 primer (5′-AGAAGGAGCCACACGA
CAGGGGTAA). The primer set used for the second
round of PCR was the S2 primer (5′-CTCCTTCAC
AAACCAGAGACCAA) and A2 primer (5′-TTCAGGC
AGCGTCTTCACAG). The second round PCR product
covering the break point was sub-cloned into a pT7Blue
plasmid vector (TaKaRa Bio). The DNA sequence was
analyzed using universal primers (M13M4 primer or T7
promoter primer) and the Big-dye terminator ver3.1 kit
(Applied Biosystems). A RACE analysis confirmed a re-
arrangement in ALK and identified ATIC (NM_004044)
as a partner of this ALK fusion mutant (Fig. 3b).
RT-PCR
First-strand cDNA was synthesized from total RNA
using the SuperScript First-Strand Synthesis System
(Invitrogen) according to the manufacturer’s instruc-
tions. RT-PCR was used to confirm the presence of the
AITC-ALK fusion gene in this case. The primer set used
was as follows: forward (5′-CCAAGCTTCCCATCAC
AGTGTACC) and reverse (5′-GAGGTCTTGCCAGCAA
AGCAGTAG). RT-PCR was used to confirm the presence
of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) in
this case. The primer set used was as follows: forward (5′-
TGGAGTCCACTGGCGTCTTC) and reverse (5′-ATGA
CGAACATGGGGGCATCAG). A RT-PCR analysis con-
firmed the ATIC-ALK fusion in tumor cells (Fig. 3c).
Based on these results, the final diagnosis was IMT.
Discussion
We herein presented the first case of IMT with an
ATIC-ALK fusion mutation primarily in the maxillofacial
region. IMTs are rare mesenchymal tumors. Different
terms have been applied to these lesions, namely,
xanthogranuloma, plasma cell granuloma, inflammatory
Fig. 3 a FISH assay with a break apart probe for the ALK gene
shows one intact yellow signal and one separated red and green
signal per nucleus in tumor cells, indicating the presence of a
rearrangement in the ALK gene. b The 5′ RACE analysis identified
ATIC as a fusion partner. The sequence of the second round PCR
product covering the fusion point (arrow) is shown. c The results of
the RT-PCR analysis for ATIC-ALK are shown. PT: Present tumor, UT:
Unrelated tumor (lung tumor), DW: Distilled Water, GAPDH:
glyceraldehydes-3-phosphate dehydrogenase
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pseudotumor (IPT), and inflammatory myofibroblastic
sarcoma [1, 6, 7]. The diverse nomenclature is descrip-
tive and reflects the uncertainty regarding the true bio-
logical nature of these lesions. In 2013, the World
Health Organization classification of soft tissue and bone
defined IMT as a distinctive neoplasm composed of
myofibroblastic and fibroblastic spindle cells accom-
panied by an inflammatory infiltrate of plasma cells,
lymphocytes, and/or eosinophils [1]. The expression
of ALK proteins is detected by anti-ALK immunohisto-
chemistry in approximately 50% of IMT cases. ALK pro-
tein expression has been shown to reliably correlate with
ALK gene rearrangements [8]. These lines of evidence
support ALK-positive IMT being a distinct neoplastic en-
tity. ALK immunostaining is an aid in the pathological
diagnosis of IMTs, as well as in the differentiation of IMTs
from other spindle cell neoplasms that fall within the
broad category of IPTs. We reviewed 12 cases of intraoss-
eous tumors of the mandible with similar histological fea-
tures in the literature (Table 1) [7, 9–19]. Six cases were
diagnosed as IPTs and 6 as IMTs in the mandible. ALK-
positive IMT/IPT in the mandible was initially reported in
2005 [10] and only 4 cases including ours have been re-
ported since then [10, 11, 19].
Thus, IMT may very rarely occur in the mandible.
Otherwise, IMT may often be misdiagnosed because diffi-
culties are associated with its histological differentiation
from other spindle cell neoplasms and reactive le-
sions. Differential diagnoses include posttraumatic
spindle cell nodules, giant cell granuloma, myofi-
broma, myoepithelioma, ameloblastic fibroma, odon-
togenic myxofibroma, IMT, a solitary fibrous tumor,
low-grade myofibroblastic sarcoma, myofibrosarcoma,
leiomyosarcoma, and spindle cell carcinoma. The im-
munohistochemical expression of the ALK protein is a
very important hallmark for differentiating IMT from
those described above. Therefore, if spindle cell lesions are
detected in the jawbone, IMT must be included in the dif-
ferential diagnosis and an immunohistochemical examin-
ation of ALK protein expression is needed.
Table 1 Clinicopathological features of IMTs in the mandible described in the present and previous reports
No. Authors (yr.) Age (yr.) Sex Diagnosis ALK-IHC FISH RT-PCR
1 Zegarelli (1974) [7] 56 F Granuloma (?IPT) NA NA NA
2 Inui (1993) [9] 63 M IPT NA NA NA
3 Brooks (2005) [10] 82 F IMT positive NA NA
4 Poh (2005) [11] 42 F IMT positive NA NA
5 Oh (2008) [12] 20 F IPT NA NA NA
6 Johann (2008) [13] 33 M IPT NA NA NA
7 Satomi (2010) [14] 14 F IMT negative NA NA
8 Date (2010) [15] 70 M IPT negative NA NA
9 Sasagawa (2011) [16] 60 M IMT NA NA NA
10 Gawande (2012) [17] 20 M IPT NA NA NA
11 Sah (2013) [18] 30 M IMT negative NA NA
12 Stringer (2014) [19] 16 M IMT positive NA NA
13 Present case 11 F IMT positive positive ATIC-ALK
ALK anaplastic lymphoma kinase, IHC immunohistochemistry, FISH Fluorescene in situ hybridization, F female, M male, IPT Inflammatory pseudotumor, IMT
Inflammatory myofibroblastic tumor, NA data not available
Fig. 4 The hypothetical schema of the gene fusion between ALK and ATIC. ATIC-ALK fusion is generated by the pericentric inversion of
chromosome 2 at the breakpoints of p23 and q35 [inv(2)(p23q35)], in which the ALK and ATIC genes are localized
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The present tumor was confirmed to have the ATIC-ALK
fusion mutation. Different ALK fusion partners, including
TPM3, TPM4, CLTC, CARS, RANBP2, ATIC, SEC31L1,
PPFIBP1, and DCTN1, in which TPM3 is the most com-
mon partner, have been identified in IMTs [5, 20–26].
ATIC-ALK fusion mutations are very rare, comprising ap-
proximately 1% of ALK-fusion mutations in anaplastic
large cell lymphomas (ALCL) [27]. The hypothetical
schema of the gene fusion between ATIC and ALK is
shown in Fig. 4 [28]. To the best of our knowledge, one
case of urinary bladder IMT with the ATIC-ALK fusion
mutation and one case of IMT arising from the hyoid
bone in a neonate with the ATIC-ALK fusion have been
reported in the literature [23, 29]. Thus, the present case
is the first IMT with the ATIC-ALK fusion mutation pri-
marily in the mandible.
The management of IMTs needs to entail complete
surgical resection, including postoperative reassessments
for at least 10 years [30]. Although the number of IMTs in
the jawbone is limited, they appear to exhibit a favorable
clinical course. However, it is important to emphasize that
IMTs occasionally behave in an aggressive manner. Poh
et al. reported the local recurrence of an intraosseous
mandibular IMT 14 months after initial surgery [11].
Sasagawa et al. described a case of multiple IMTs in-
volving the cranium, mandible, ischium, and calca-
neus [16]. The ALK inhibitor, crizotinib, was recently
demonstrated to be clinically beneficial for IMTs with
ALK fusion mutations [26, 31–33].
Conclusion
IMTs are rare lesions in the mandible. The general
consensus is that IMTs encompass a group of hetero-
geneous lesions with various biological behaviors. How-
ever, a proportion of cases are genuine neoplasms with
the involvement of ALK fusion mutations. The recogni-
tion of this diagnostic entity is important for selecting ap-
propriate treatments.
To the best of our knowledge, we are the first to de-
scribe IMT with the ATIC-ALK fusion mutation in the
mandible.
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